Ivan Saltzman, the co-founder of Dis-Chem Pharmacies, has revealed plans to retire from his executive director position in June 2026, signifying a notable evolution in leadership at one of South Africa’s premier healthcare retailers, while he continues to contribute strategically as a non-executive director and deputy chairperson.
Since establishing Dis-Chem in 1978 with his wife Lynette, Saltzman has steered the company from its humble origins as a single discount pharmacy in Johannesburg to a sprawling network encompassing over 300 stores and 44 clinics by mid-2025, fostering innovations in affordable healthcare access and private-label products that have resonated with cost-conscious consumers amid economic volatility.
The company’s chairperson has highlighted Saltzman’s pivotal influence in propelling Dis-Chem’s expansion, noting that his enduring expertise will remain invaluable in a more advisory capacity, whereas the chief executive has underscored how Saltzman’s vision has not only constructed a robust brand but also transformed the sector and enhanced public wellbeing on a large scale.
Saltzman himself has indicated that this shift aligns with the organisation’s efforts to fortify its management framework, expressing optimism about providing ongoing support from a strategic vantage point without the demands of operational involvement.
READ – New Faces at Dis-Chem Aim to Steady Market
This development forms part of a phased generational handover within the Saltzman family, including his son Saul’s forthcoming resignation as executive director in February 2026 after 19 years, though Saul will retain a non-independent non-executive board seat, following earlier changes such as Ivan’s departure from the chief executive role in 2023, Lynette’s executive exit in 2022, and a substantial R6.8 billion share reallocation to brothers Dan and Mark earlier this year.
In the broader context, Dis-Chem’s trajectory reflects resilience in South Africa’s pharmacy retail sector, which is projected to expand at a compound annual growth rate of 11.4 per cent from 2025 to 2030, driven by rising demand for generics and wellness services, with the total pharmaceutical retail market valued at approximately $3.1 billion in 2024, according to Grand View Research. As reported by Reuters, Dis-Chem achieved an 8.7 per cent revenue increase to R21.3 billion for the half-year ending August 2025, bolstered by 11.1 per cent wholesale growth to R16.8 billion, outperforming competitors like Clicks, whose half-year revenues rose 6.2 per cent to R23.2 billion.
Looking ahead, this leadership recalibration positions Dis-Chem to navigate challenges such as regulatory pressures on pricing and supply chain disruptions, potentially sustaining its market share of around 25 per cent in the fragmented sector, as the company aspires to solidify its status as a comprehensive healthcare authority in an increasingly digital and consumer-centric landscape, per insights from BusinessTech.